Protagonist Therapeutics Inc. (PTGX)
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PTGX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.92B
- P/E (TTM)
- 25.67
- Forward P/E
- 348.79
- EPS (TTM)
- $4.73
- Dividend yield
- None
- 52-week range
- 77.00 – 160.81
- Day range
- 120.15 – 125.74
- Volume / Avg
- 600.73K / 668.45K
- Beta
- —
- Shares outstanding
- 65.27M
52-week range
PTGX stock today
On Nov 20, PTGX ended the session at $121.40, shedding $2.62 (2.11%), versus the S&P 500's 3.70% decline. Shares are 24.5% below their 52-week high of $160.81, set on Aug 19, 2026 and 57.7% above the 52-week low of $77.00, in the middle of the past year's range. PTGX is up 39.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 42.2%.
Protagonist Therapeutics trades at 25.7x its trailing twelve-month earnings per share of $4.73. Its forward P/E of 348.8x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Protagonist Therapeutics
Company profileProtagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Dinesh V. Patel Ph.D.
- Headquarters
- Newark, CA
- Employees
- 149
- IPO year
- 2016
- Website
- protagonist-inc.com
Financial highlights
Full financialsIn fiscal 2025, Protagonist Therapeutics generated $46.0 million in revenue, down 89.4% from fiscal 2024, its first annual decline since 2022. Protagonist Therapeutics reported a net loss of $130.1 million, compared with net income of $275.2 million a year earlier. Operating margin was -343.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M |
| Growth | -89.41% | +624.05% | +125.73% | -2.84% | -4.44% |
| Net income | $-130.15M | $275.19M | $-78.95M | $-127.39M | $-125.55M |
| EPS (diluted) | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$182.36+50.21%
- Strong buy 3
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.62 vs $2.58
- Surprise
- -124.03%
PTGX news
All PTGX news- J&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold?NasdaqJNJ, LLY, PTGX
- Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass EstimatesNasdaqPTGX, LQDA
- Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue EstimatesNasdaqNAGE, PTGX
- Noteworthy ETF Outflows: IJT, PTGX, VSAT, TGTXNasdaqIJT, PTGX, VSAT, TGTX
- Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings GrowthNasdaqPTGX, QGEN
- Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-TermNasdaq
- Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?Nasdaq
- Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty CompounderSeeking Alpha
Protagonist Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SMMTSummit Therapeutics Inc. | 9.95 | -5.87% | $7.96B | vs PTGX |
| RYTMRhythm Pharmaceuticals Inc. | 112.36 | -3.80% | $7.79B | vs PTGX |
| ALKSAlkermes plc | 44.94 | -2.69% | $7.55B | vs PTGX |
| PRAXPraxis Precision Medicines Inc. | 300.43 | -3.37% | $8.40B | vs PTGX |
| KNSAKiniksa Pharmaceuticals International plc Class A | 93.90 | +0.38% | $7.38B | vs PTGX |
| AMRXAmneal Pharmaceuticals Inc. Class A | 21.12 | -1.26% | $7.36B | vs PTGX |
| CYTKCytokinetics Incorporated | 50.78 | -1.32% | $7.07B | vs PTGX |
| MDGLMadrigal Pharmaceuticals Inc. | 379.10 | -4.45% | $8.81B | vs PTGX |
Indexes, lists and sector
Protagonist Therapeutics stock FAQ
What is Protagonist Therapeutics's stock price today?
PTGX last traded at $121.40 as of Nov 20, 4:00 PM EST, down 2.11% on the day. Prices are delayed at least 15 minutes.
What is PTGX's P/E ratio?
PTGX trades at a trailing P/E ratio of 25.67 and a forward P/E of 348.79.
Who is Protagonist Therapeutics's CEO?
Dr. Dinesh V. Patel Ph.D. is the chief executive officer of Protagonist Therapeutics Inc., which has about 149 employees.
What is the PTGX 52-week high?
The 52-week high for PTGX is $160.81 and the 52-week low is $77.00. The stock is currently 24.5% below its high.